Featured Story | | | Wednesday, August 2, 2017 Amplyx Pharmaceuticals has raised $67 million to fund antifungal R&D. The series C sets Amplyx up to take its lead broad-spectrum antifungal candidate into phase 2 later this year. |
|
|
| This week's sponsor is FierceBiotech. | |  | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Top Stories Wednesday, August 2, 2017 Yale University has teamed up with cancer biotech X4 Pharmaceuticals to work on its therapy for WHIM syndrome, a rare genetic disorder that plays havoc with the immune system but has no approved treatment. Wednesday, August 2, 2017 Agilis Biotherapeutics has formed a joint venture with Japan’s Gene Therapy Research Institution. The alliance gives Agilis a base in Japan and a partnership with a fellow CNS specialist to support its development of adeno-associated virus vectors and gene therapies. Wednesday, August 2, 2017 Here's more of Wednesday's biopharma news of note. Tuesday, August 1, 2017 Icon has bought health research and commercialization company Mapi for integration into its existing late-phase team, a deal that bumped Icon’s whole-year revenue guidance to $1.77 billion on the upper end. Wednesday, August 2, 2017 Patients with a specific type of acute myeloid leukemia have their first treatment option with the FDA’s decision on Tuesday to approve Idhifa from partners Celgene and Axios. Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. | 
